CERC Cerecor Inc.

-0.07  -2%
Previous Close 3.59
Open 3.61
Price To Book 8.59
Market Cap 151,031,739
Shares 42,906,744
Volume 48,331
Short Ratio
Av. Daily Volume 176,309

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released December 5, 2016 - endpoint not met.
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
Major depressive disorder (MDD)
Phase 1 final data released July 1, 2019.
Neurogenic Orthostatic Hypotension (nOH)
NDA planned of 2H 2020.
CERC 801
Phosphoglucomutase 1 (PGM1) deficiency

Latest News

  1. Cerecor Reports Second Quarter 2019 Results
  2. FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG
  3. What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?
  4. CERC: CDG FIRST Trial Underway…
  5. Cerecor Announces First Patient Enrolled in CDG FIRST Trial
  6. Drugmakers raised prices of over 40 prescription drugs
  7. Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)
  8. 18 Stocks Joining The Russell Indices
  9. Cerecor Added to Russell 3000® Index
  10. Cerecor Appoints Keith Schmidt to its Board of Directors
  11. Cerecor Set to Join Russell 3000® Index
  12. CERC: Completion of Phase 1 Trial of CERC-801…
  13. Cerecor Reports First Quarter 2019 Results
  14. Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years
  15. Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers
  16. CERC: Positive Results for Phase 1 Trial of CERC-301…
  17. Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)
  18. Cerecor Announces Leadership Changes
  19. CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…
  20. Cerecor Reports Fourth Quarter and Full Year 2018 Results